Ischemix LLC
Records under this name other than the patents Ischemix LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 7 of 7 · Back to Ischemix LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,772,249 | Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury Lapsed on the fee record Ended Jul 8, 2026 · High confidence | Lapsed on the fee record | Ended Jul 8, 2026 | High confidence |
| US 8,772,250 | Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury Lapsed on the fee record Ended Jul 8, 2026 · High confidence | Lapsed on the fee record | Ended Jul 8, 2026 | High confidence |
| US 11,213,509 | Compositions and methods for treating traumatic brain injury Lapsed on the fee record Ended Jan 4, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 4, 2026 | From the USPTO record |
| US 8,772,237 | Compositions and methods for counteracting effects of reactive oxygen species and free radicals Formerly held Term ended Term ended May 10, 2021 · From the USPTO record | Term ended | Term ended May 10, 2021 | From the USPTO record |
| US 8,034,774 | Compositions and methods for counteracting effects of reactive oxygen species and free radicals Lapsed on the fee record Ended Oct 11, 2019 · From the USPTO record | Lapsed on the fee record | Ended Oct 11, 2019 | From the USPTO record |
| US 6,890,896 | Compositions and methods for counteracting effects of reactive oxygen species and free radicals Lapsed on the fee record Ended May 10, 2017 · From the USPTO record | Lapsed on the fee record | Ended May 10, 2017 | From the USPTO record |
| US 7,524,819 | Compositions and methods for counteracting effects of reactive oxygen species and free radicals Formerly held Lapsed on the fee record Ended Apr 28, 2017 · From the USPTO record | Lapsed on the fee record | Ended Apr 28, 2017 | From the USPTO record |